news + headlines

Over the next five years, the Canadian Institutes of Health Research (CIHR) will inject $2.7 million into the Canadian Observational Cohort (CANOC). It is the country’s only longitudinal study of more than 10,000 HIV-positive individuals receiving antiretroviral therapy (ART) in Canada.
HIV is no longer a death sentence. It’s a manageable chronic condition – one that we can test for, and take precautions against. And yet, Canadian Blood Services and Héma-Québec still maintain an inexplicable ban on blood donations from men who have sex with men.
Thousands upon thousands of collective footsteps treaded along the diverse streets of Canada from September 13 to 21 to show support for the 71,300 Canadians living with HIV/AIDS.
Treatment with pre-exposure prophylaxis (PrEP) does not involve a significant risk of HIV drug resistance should seroconversion occur, results from the iPrEx study published in the online edition of the Journal of Infectious Diseases demonstrate. The only cases of drug resistance among people who had taken PrEP involved individuals with unrecognised acute HIV infection when they started therapy.